PL2131818T3 - Nowa postać dawkowania - Google Patents
Nowa postać dawkowaniaInfo
- Publication number
- PL2131818T3 PL2131818T3 PL08717221T PL08717221T PL2131818T3 PL 2131818 T3 PL2131818 T3 PL 2131818T3 PL 08717221 T PL08717221 T PL 08717221T PL 08717221 T PL08717221 T PL 08717221T PL 2131818 T3 PL2131818 T3 PL 2131818T3
- Authority
- PL
- Poland
- Prior art keywords
- dosage form
- novel dosage
- novel
- dosage
- Prior art date
Links
- 239000002552 dosage form Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/282—Organic compounds, e.g. fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Molecular Biology (AREA)
- Rheumatology (AREA)
- Psychology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Cardiology (AREA)
- Anesthesiology (AREA)
- Diabetes (AREA)
- Child & Adolescent Psychology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US89226707P | 2007-03-01 | 2007-03-01 | |
| PCT/EP2008/052430 WO2008104590A2 (en) | 2007-03-01 | 2008-02-28 | Novel dosage form |
| EP08717221.9A EP2131818B1 (en) | 2007-03-01 | 2008-02-28 | Novel dosage form |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL2131818T3 true PL2131818T3 (pl) | 2014-08-29 |
Family
ID=39248198
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL08717221T PL2131818T3 (pl) | 2007-03-01 | 2008-02-28 | Nowa postać dawkowania |
Country Status (29)
| Country | Link |
|---|---|
| US (1) | US20110014283A1 (enExample) |
| EP (1) | EP2131818B1 (enExample) |
| JP (2) | JP5743177B2 (enExample) |
| KR (1) | KR101504371B1 (enExample) |
| CN (1) | CN101674806B (enExample) |
| AR (1) | AR065529A1 (enExample) |
| AU (1) | AU2008220795B2 (enExample) |
| BR (1) | BRPI0807882A2 (enExample) |
| CA (1) | CA2679529A1 (enExample) |
| CL (1) | CL2008000596A1 (enExample) |
| CO (1) | CO6220900A2 (enExample) |
| CR (1) | CR11013A (enExample) |
| DK (1) | DK2131818T3 (enExample) |
| DO (1) | DOP2009000207A (enExample) |
| EA (1) | EA019865B1 (enExample) |
| ES (1) | ES2463468T3 (enExample) |
| HR (1) | HRP20140390T1 (enExample) |
| IL (1) | IL200619A (enExample) |
| MA (1) | MA31198B1 (enExample) |
| MX (1) | MX2009009362A (enExample) |
| NZ (1) | NZ579374A (enExample) |
| PE (1) | PE20090114A1 (enExample) |
| PL (1) | PL2131818T3 (enExample) |
| PT (1) | PT2131818E (enExample) |
| SI (1) | SI2131818T1 (enExample) |
| TW (1) | TWI424856B (enExample) |
| UA (1) | UA102515C2 (enExample) |
| WO (1) | WO2008104590A2 (enExample) |
| ZA (1) | ZA200905866B (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9108948B2 (en) | 2006-06-23 | 2015-08-18 | Abbvie Inc. | Cyclopropyl amine derivatives |
| CA2655604C (en) | 2006-06-23 | 2016-08-09 | Abbott Laboratories | Cyclopropyl amine derivatives |
| EP2328587A1 (en) * | 2008-08-29 | 2011-06-08 | Glaxo Group Limited | Dosage form comprising 1-isopropyl-4-{ [4-(tetrahydro-2h-pyran- 4-yloxy)phenyl]carbonyl}hexahydro-1h-1,4-diazepine or a salt thereof |
| US9186353B2 (en) | 2009-04-27 | 2015-11-17 | Abbvie Inc. | Treatment of osteoarthritis pain |
| WO2011051423A1 (en) | 2009-11-02 | 2011-05-05 | Glaxo Group Limited | Treatment or prophylaxis of dementia, neurodegenerative disorders, schizophrenia, adhd, somnolence or epilepsy |
| US8853390B2 (en) | 2010-09-16 | 2014-10-07 | Abbvie Inc. | Processes for preparing 1,2-substituted cyclopropyl derivatives |
| US20130244943A1 (en) | 2011-09-06 | 2013-09-19 | Allergan, Inc. | Hyaluronic acid-collagen matrices for dermal filling and volumizing applications |
| ES2764660T3 (es) | 2014-12-16 | 2020-06-04 | Axovant Sciences Gmbh | Compuestos de amida de quinuclidina sustituida geminal como agonistas de receptores alfa-7 nicotínicos de acetilcolina |
| WO2016201096A1 (en) | 2015-06-10 | 2016-12-15 | Forum Pharmaceuticals, Inc. | Aminobenzisoxazole compounds as agonists of a7-nicotinic acetylcholine receptors |
| HK1253295A1 (zh) | 2015-08-12 | 2019-06-14 | Axovant Sciences Gmbh | 作为7-烟碱乙酰胆碱受体的激动剂的偕取代的氨基苯并异恶唑化合物 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2170892A1 (en) * | 1993-09-03 | 1995-03-09 | Patrick Gerard Faulkner | Stabilized tablet formulation |
| JP5524435B2 (ja) * | 1998-12-01 | 2014-06-18 | ドクター レディーズ ラボラトリーズ リミティド | 新規医薬組成物及びその調製のための方法 |
| US20040037869A1 (en) * | 2002-08-16 | 2004-02-26 | Douglas Cleverly | Non-animal product containing veterinary formulations |
| KR100765027B1 (ko) * | 2002-12-20 | 2007-10-09 | 글락소 그룹 리미티드 | 신경 장애 치료용 벤즈아제핀 유도체 |
| CN101274911B (zh) * | 2003-06-17 | 2011-01-26 | 艾尼纳制药公司 | 用于治疗5ht2c受体相关病症的苯并氮杂卓衍生物 |
| WO2005000354A1 (ja) * | 2003-06-30 | 2005-01-06 | Takeda Pharmaceutical Company Limited | 排尿障害予防・治療剤 |
| WO2005042491A1 (en) * | 2003-10-22 | 2005-05-12 | Arena Pharmaceuticals, Inc. | Benzazepine derivatives and methods of prophylaxis or treatment of 5ht2c receptor associated diseases |
| US20060002986A1 (en) * | 2004-06-09 | 2006-01-05 | Smithkline Beecham Corporation | Pharmaceutical product |
| AR051919A1 (es) * | 2004-06-18 | 2007-02-21 | Glaxo Group Ltd | Compuesto derivado de benzazepina, composicion farmaceutica que lo comprende, su uso para la fabricacion de un medicamento y procedimientos para preparar el compuesto |
| JP2006022039A (ja) * | 2004-07-08 | 2006-01-26 | Towa Yakuhin Kk | 高い安定性を有するシンバスタチン固形製剤 |
| GB0418267D0 (en) * | 2004-08-16 | 2004-09-15 | Glaxo Group Ltd | Novel compounds |
-
2008
- 2008-02-27 CL CL200800596A patent/CL2008000596A1/es unknown
- 2008-02-28 PT PT87172219T patent/PT2131818E/pt unknown
- 2008-02-28 EA EA200970817A patent/EA019865B1/ru not_active IP Right Cessation
- 2008-02-28 CA CA002679529A patent/CA2679529A1/en not_active Abandoned
- 2008-02-28 AR ARP080100842A patent/AR065529A1/es unknown
- 2008-02-28 ES ES08717221.9T patent/ES2463468T3/es active Active
- 2008-02-28 EP EP08717221.9A patent/EP2131818B1/en not_active Not-in-force
- 2008-02-28 HR HRP20140390AT patent/HRP20140390T1/hr unknown
- 2008-02-28 SI SI200831205T patent/SI2131818T1/sl unknown
- 2008-02-28 PE PE2008000398A patent/PE20090114A1/es not_active Application Discontinuation
- 2008-02-28 WO PCT/EP2008/052430 patent/WO2008104590A2/en not_active Ceased
- 2008-02-28 JP JP2009551216A patent/JP5743177B2/ja not_active Expired - Fee Related
- 2008-02-28 AU AU2008220795A patent/AU2008220795B2/en not_active Ceased
- 2008-02-28 CN CN2008800144640A patent/CN101674806B/zh not_active Expired - Fee Related
- 2008-02-28 MX MX2009009362A patent/MX2009009362A/es active IP Right Grant
- 2008-02-28 PL PL08717221T patent/PL2131818T3/pl unknown
- 2008-02-28 NZ NZ579374A patent/NZ579374A/en not_active IP Right Cessation
- 2008-02-28 UA UAA200909976A patent/UA102515C2/ru unknown
- 2008-02-28 BR BRPI0807882-3A2A patent/BRPI0807882A2/pt not_active IP Right Cessation
- 2008-02-28 KR KR1020097020444A patent/KR101504371B1/ko not_active Expired - Fee Related
- 2008-02-28 US US12/528,492 patent/US20110014283A1/en not_active Abandoned
- 2008-02-28 DK DK08717221.9T patent/DK2131818T3/da active
- 2008-02-29 TW TW097106936A patent/TWI424856B/zh not_active IP Right Cessation
-
2009
- 2009-08-24 ZA ZA200905866A patent/ZA200905866B/xx unknown
- 2009-08-27 IL IL200619A patent/IL200619A/en not_active IP Right Cessation
- 2009-08-28 DO DO2009000207A patent/DOP2009000207A/es unknown
- 2009-08-31 MA MA32184A patent/MA31198B1/fr unknown
- 2009-09-02 CR CR11013A patent/CR11013A/es unknown
- 2009-09-10 CO CO09097361A patent/CO6220900A2/es not_active Application Discontinuation
-
2014
- 2014-09-19 JP JP2014191832A patent/JP2015038098A/ja not_active Withdrawn
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUS1800007I1 (hu) | Gyógyászati készítmény | |
| GB0709031D0 (en) | Pharmaceutical compounds | |
| IL201366A0 (en) | Pharmaceutical compounds | |
| EP2133095A4 (en) | PHARMACEUTICAL COMPOSITION | |
| EP2133094A4 (en) | PHARMACEUTICAL COMPOSITION | |
| GB0721095D0 (en) | Pharmaceutical compounds | |
| GB0707087D0 (en) | Pharmaceutical compounds | |
| IL200125A0 (en) | Pharmaceutical composition | |
| GB0810615D0 (en) | Novel pharmaceutical | |
| GB0725214D0 (en) | Pharmaceutical compounds | |
| GB0704932D0 (en) | Pharmaceutical compounds | |
| EP2224805A4 (en) | PHARMACEUTICAL COMPOSITION | |
| GB0710439D0 (en) | Oral dosage form | |
| EP2224915A4 (en) | PHARMACEUTICAL COMPOSITIONS | |
| IL200619A0 (en) | Novel dosage form | |
| GB0721669D0 (en) | Pharmaceutical compounds | |
| EP2224808A4 (en) | PHARMACEUTICAL COMPOSITION | |
| GB0616794D0 (en) | Solid dosage form | |
| GB0810617D0 (en) | Novel pharmaceutical | |
| IL205975A0 (en) | Pharmaceutical composition | |
| GB0717450D0 (en) | Medicament | |
| IL205931A0 (en) | Pharmaceutical composition | |
| GB0717882D0 (en) | Novel pharmaceutical | |
| GB0704123D0 (en) | Dosage form | |
| GB0802576D0 (en) | Dosage form |